Transgene Biotek share news, announcements and annual reports
BSE: 526139Healthcare ServicesSmall Cap
Share price at the BSE close on 2 Nov 2026. Previous close ₹2.33.
2 Nov: open ₹2.38, high ₹2.57, low ₹2.29
- Under BSE's graded surveillance, stage 0, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹19 Cr4,238th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.22
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −2.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 2.05
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 21,872
Transgene Biotek share news and announcements
487 announcements, routine notices left out, newest first. Page 5 of 10.
Jan 2021
3 Jan · Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Dec 2020
24 Dec · Intimation Of Incorporation Of A Wholly Owned Subsidiary Company.
Nov 2020
3 Nov · Board meeting
Meeting on 10 Nov 2020: quarterly results
Oct 2020
13 Oct · Submission Of Regulation 40(9) Of SEBI (LODR) Regulations 2015.
13 Oct · Submission Of Regulation 40(9) Of SEBI (LODR) Regulations 2015.
10 Oct · Shareholding for the Period Ended September 30, 2020
Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click ....8 Oct · Compliance Certificate Pursuant To Regulation 7(3).
3 Oct · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....2 Oct · Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2020
30 Sep · Meeting
Aug 2020
28 Aug · Reg. 34 (1) Annual Report
14 Aug · Board meeting
Meeting on 24 Aug 2020: quarterly results and annual general meeting
Jul 2020
9 Jul · Shareholding for the Period Ended June 30, 2020
Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click ....2 Jul · Disclosure Of Material Impact Of Pandemic Of Corona Virus (Covid-19) Under Regulation 30(3) Of The SEBI (Listing Obligations &Amp; Disclosure Requirements) Regulations, 2015.
2 Jul · Submission Of Cash Flows Statement Standalone And Consolidated For The Year Ended 31 St March 2020.
2 Jul · Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2020
29 Jun · Submission Of Cash Flows Statement Standalone And Consolidated For The Half Year Ended 31St March 2020. This Has Reference To Your Email Dated 24Th June 2020 On The Subject.
May 2020
28 May · Board meeting
Meeting on 3 Jun 2020: audited results28 May · Submission Of Regulations 40(9) Of SEBI (LODR) Regulations 2015.
Apr 2020
27 Apr · Targeted Drug Against SARS Covid 19 Infections.
17 Apr · Shareholding for the Period Ended March 31, 2020
Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click ....10 Apr · Receipt Of Certificate Of Patent From Australia On Oral Delivery Of Biologically Active Molecules.
4 Apr · Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Mar 2020
Feb 2020
25 Feb · Board meeting
Meeting on 4 Mar 2020
Jan 2020
24 Jan · Board meeting
Meeting on 4 Feb 2020: quarterly results22 Jan · Management
17 Jan · Shareholding for the Period Ended December 31, 2019
Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click ....9 Jan · Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 03 Jan · This Is To Inform You That As A Part Of The Rearrangement Of Affairs Amongst The Promoters Group, There Will Be Some Inter Se Transfer Of Shares Among Members Of The Promoters Group During The Next 30 Days.
Nov 2019
12 Nov · Management
12 Nov · Board meeting
11 Nov · Receipt Of Certificate Of Patent From Japan On Oral Delivery Of Biologically Active Molecules.
4 Nov · Board meeting
Meeting on 12 Nov 2019: quarterly results